Table 1.

Age and sex distribution of study subjects

Vaccine group	Gender		χ 2	p	Age				χ 2	p
	Male	Female			15–24	25–34	35–44	45–50
I	99	144	6.757	0.239	37	97	88	21	22.048	0.107
II	50	101			19	62	56	14
III	107	143			48	106	77	19
IV	65	86			40	62	39	10
V	51	59			21	52	25	12
VI	48	83			31	49	41	10